Biotechnology News and Research

RSS

IntegraGen’s ARISk Test looks at 65 genetic markers associated with autism

IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, today announced the launch of the ARISk- Risk Assessment Test, a gender specific, genetic screening test that looks at 65 genetic markers associated with Autism Spectrum Disorder.

5 Apr 2012

CHD8, SNC2A and KATNAL2 gene mutations lead to ASDs

Mutations in three new genes have been linked to autism, according to new studies including one with investigators at Mount Sinai School of Medicine. All three studies include lead investigators of the Autism Sequencing Consortium.

5 Apr 2012

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting.

5 Apr 2012

Reactivation of p53 may be a highly selective treatment modality for virally-induced lymphoma

Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six months after diagnosis.

4 Apr 2012

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.

4 Apr 2012

Nuvilex realizes important role for Cell-in-a-Box technology

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions through acquisition of SG Austria assets, realizes the important role for Cell-in-a-Box technology and aims to bring to light its use in the production of therapeutic antibodies for clinically important diseases.

4 Apr 2012

Causes of traumatic brain injury in older population

As the population ages in western countries, traumatic brain injury (TBI) resulting mainly from falls is on the rise among the elderly, introducing new complications and treatment challenges, according to an article in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc.

4 Apr 2012

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

UCB and Amgen announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

4 Apr 2012

BioMed closes new $400M senior unsecured term loan facility

BioMed Realty Trust, Inc. announced today that the company has closed a new $400 million senior unsecured term loan facility. The new facility matures on March 30, 2017.

4 Apr 2012

AIT renews ISO 9001:2008 certification

Applied Instrument Technologies (AIT), a leading manufacturer of process analyzers for the refining, petrochemical, chemical, steel, biotechnology and emissions markets has renewed its ISO 9001:2008 certification.

4 Apr 2012

Bio-Path 2011 net loss increases to $2,363,344

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year ended December 31, 2011.

4 Apr 2012

Genetic counseling does not help parents in disclosing their breast cancer information to children

When a mother undergoes genetic testing to determine whether she carries a gene for hereditary breast cancer, the parents must then decide whether and how to share this risk information with their children.

3 Apr 2012

TLR4/MD-2 protein complex triggers morphine-induced inflammation

A University of Colorado Boulder-led research team has discovered that two protein receptors in the central nervous system team up to respond to morphine and cause unwanted neuroinflammation, a finding with implications for improving the efficacy of the widely used painkiller while decreasing its abuse potential.

3 Apr 2012

RPS selects DATATRAK as preferred vendor

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced RPS selected DATATRAK as a preferred vendor and joined DATATRAK's CRO Connect Partner program.

3 Apr 2012

Biotage adds Isolera Spektra to Flash Chromatography product line

Biotage, a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced Isolera Spektra. The new Isolera Spektra expands the scope of application of Biotage's market-leading Flash Chromatography product line by increasing efficiency with significant solvent and time saving capabilities as well as enabling purity assessment technology.

2 Apr 2012

Teva reports successful outcome of three debut financings

Teva Pharmaceutical Industries Limited announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion senior unsecured fixed-rate syndicated term loan facility.

2 Apr 2012

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

AlloCure closes $25 million Series B venture financing

AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $25 million Series B venture financing.

2 Apr 2012

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

2 Apr 2012

Life Technologies expands TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the expansion to its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools designed to detect an additional 241 of the most common mutations in 21 cancer genes.

2 Apr 2012